Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Authors: Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt

Source: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Subject Terms: Clinical trials, deucravacitinib, maintenance of response, onset of action, phase 3, psoriasis, Dermatology, RL1-803

File Description: electronic resource

Relation: https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753

Access URL: https://doaj.org/article/565ff6e9db3f40f3996833c3bba76026

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Authors: April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp

Source: Dermatology and Therapy, Vol 14, Iss 8, Pp 2235-2248 (2024)

Subject Terms: Clinical trial, Minimum clinically important difference, Psoriasis, Quality of life, Treatment efficacy, Dermatology, RL1-803

File Description: electronic resource

Relation: https://doaj.org/toc/2193-8210; https://doaj.org/toc/2190-9172

Access URL: https://doaj.org/article/eb30f9d6f1ac4e2b804fb11e94392dce